ZURA
NASDAQ HealthcareZura Bio Limited - Class A Ordinary shares
Biotechnology
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
๐ Market Data
| Price | $5.21 |
|---|---|
| Volume | 408,154 |
| Market Cap | 494.33M |
| Beta | 0.240 |
| RSI (14-Day) | 38.5 |
| 200-Day MA | $4.23 |
| 50-Day MA | $6.02 |
| 52-Week High | $7.44 |
| 52-Week Low | $0.98 |
| Forward P/E | -52.10 |
| Price / Book | 3.78 |
๐ฏ Investment Strategy Scores
ZURA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (52/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (13/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ZURA in your text
Paste any article, transcript, or post โ the tool will extract ZURA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.